David John Allsup

29PUBLICATIONS
109CO-AUTHORS
Haematological tumoursCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jun 21, 2026
An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

|May 08, 2026
Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta-Analysis.

|Mar 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

David J Allsup, David A Cairns, E Faye Samy

|Mar 12, 2026
Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.

Stefano Molica, David Allsup

|Mar 04, 2026
Indirect comparison of continuous and time‑limited BTKi-venetoclax in TP53‑wild‑type CLL: does IGHV still matter?

Stefano Molica, Diana Giannarelli, David Allsup

|Jan 29, 2026
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Diyanath Ranasinghe, Wei-Yu Lin, Sarah E Fordham

Pageof 5

Frequent Collaborators

11 joint publications

Stefano Molica

4 joint publications

Claire Elstob

4 joint publications

Wei-Yu Lin

3 joint publications

Jude Fitzgibbon